# US 2021/0277054 A1 · Chromatography resin and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277054 A1
- Document ID: US20210277054A1
- Status: Published application
- Kind: A1
- Application number: 17/173,767
- Filed: 2021-02-11
- Published: 2021-09-09
- Earliest claimed: 2020-02-11
- Assignees: ImmunityBio, Inc.
- Applicants: HCW Biologics, Inc.
- Inventors: Hing C. Wong; Jin-an Jiao; Caitlin Prendes
- Web page: https://patentgrep.com/patent/US20210277054A1

## CPC

- C07K 1/22: Affinity chromatography or related techniques based upon selective absorption processes
- B01D 15/3809: {of the antigen-antibody type, e.g. protein A, G or L chromatography}
- B01D 61/027: {Nanofiltration}
- B01D 61/145: {Ultrafiltration}
- B01D 61/58: Multistep processes
- C07K 14/5443: {IL-15}
- C07K 14/7155: {for interleukins [IL]}
- C07K 14/745: Blood coagulation or fibrinolysis factors
- C07K 16/36: against blood coagulation factors
- B01D 2315/16: Diafiltration
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

An affinity chromatography resin comprising an anti-tissue factor antibody or antigen-binding fragment thereof attached to a base resin, and methods of using the same.

## Claims

### Claim 1

An affinity chromatography resin comprising an anti-tissue factor antibody or antigen-binding fragment thereof comprising a heavy chain variable domain comprising CDRs of SEQ ID NOs: 1, 2 or 9, and 3, and a light chain variable domain comprising CDRs of SEQ ID NOs: 4, 5, and 6, attached to a base resin.

### Claim 2 (depends on 1)

The affinity chromatography resin of claim 1, wherein the heavy chain variable domain comprises a sequence that is at least 90% identical to SEQ ID NO: 7, and the light chain variable domain comprises a sequence that is at least 90% identical to SEQ ID NO: 8.

### Claim 3 (depends on 2)

The affinity chromatography resin of claim 2, wherein the heavy chain variable domain comprises SEQ ID NO: 7, and the light chain variable domain comprises SEQ ID NO: 8.

### Claim 4 (depends on 1)

The affinity chromatography resin of claim 1, wherein the base resin is sepharose.

### Claim 5 (depends on 1)

The affinity chromatography resin of claim 1, wherein the base resin is any support material.

### Claim 6 (depends on 5)

The affinity chromatography resin of claim 5, wherein the support material is agarose or a capto resin.

### Claim 7 (depends on 1)

The affinity chromatography resin of claim 1, wherein the anti-tissue factor antibody or antigen-binding fragment thereof is non-covalently attached to the base resin.

### Claim 8 (depends on 1)

The affinity chromatography resin of claim 1, wherein the anti-tissue factor antibody or antigen-binding fragment thereof is covalently attached to the base resin.

### Claim 9 (depends on 8)

The affinity chromatography resin of claim 8, wherein the anti-tissue factor antibody or antigen-binding fragment thereof is covalently attached to the base resin through the formation of a disulfide bond between a cysteine in the anti-tissue factor antibody or antigen-binding fragment thereof and a chemical group on the base resin.

### Claim 10 (depends on 8)

The affinity chromatography resin of claim 8, wherein the anti-tissue factor antibody or antigen-binding fragment thereof is covalently attached to the base resin through the formation of a covalent bond between a free amine of the anti-tissue factor antibody or antigen-binding domain and a chemical group on the base resin.

### Claim 11 (depends on 10)

The affinity chromatography resin of claim 10, wherein the base resin is CNBr-activated or N-hydroxysuccinimide (NHS)-activated solid support material.

### Claim 12 (depends on 10)

The affinity chromatography resin of claim 10, wherein the covalent bond is represented by Formula I below:
wherein R represents the anti-tissue factor antibody or antigen-binding fragment thereof.

### Claim 13 (depends on 1)

A kit comprising an affinity chromatography resin of claim 1.

### Claim 14 (depends on 1)

A method of purifying a tissue factor-containing protein comprising the use of the affinity chromatography resin of claim 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the method comprises:
loading the affinity chromatography resin with a liquid comprising the tissue factor-containing protein;
washing the affinity chromatography resin using one or more wash buffer(s); and
eluting the tissue factor-containing protein using an elution buffer.

### Claim 16 (depends on 15)

The method of claim 15, wherein the liquid comprising the tissue factor-containing protein is a clarified liquid culture medium.

### Claim 17 (depends on 15)

The method of claim 15, wherein the liquid comprising the tissue factor-containing protein comprises a cell lysate.

### Claim 18 (depends on 15)

The method of claim 15, wherein the one or more wash buffer(s) are:
(i) a first wash buffer comprising phosphate buffered saline; and
(ii) a second wash buffer comprising about 0.01 M to about 0.2 M citrate and having a pH of about 4.5 to about 5.5.

### Claim 19 (depends on 18)

The method of claim 18, wherein:
(i) the first wash buffer is phosphate buffered saline; and
(ii) the second wash buffer is 0.1 M citrate, pH 5.0.

### Claim 20 (depends on 15)

The method of claim 15, wherein the elution buffer comprises 0.01 M to about 0.2 M acetate and has a pH of about 2.5 to about 3.5.

### Claim 21 (depends on 20)

The method of claim 20, wherein the elution buffer comprises 0.1 M acetate and has a pH of about 2.9.

### Claim 22 (depends on 14)

A method of manufacturing a tissue factor-containing protein comprising:
(i) purifying a tissue factor-containing protein using the method of claim 14; and
(ii) performing one or more additional unit operations on an eluate obtained from step (i).

### Claim 23 (depends on 22)

The method of claim 22, wherein the one or more additional unit operations comprises, in sequential order:
performing low pH viral inactivation;
performing depth filtration;
performing polishing chromatography;
performing nanofiltration; and
performing ultrafiltration and diafiltration (UF/DF).

### Claim 24 (depends on 14)

The method of claim 14, wherein the tissue factor-containing protein is a single-chain chimeric polypeptide.

### Claim 25 (depends on 24)

The method of claim 24, wherein the single-chain chimeric polypeptide comprises:
(i) a first target-binding domain;
(ii) a soluble tissue factor domain; and
(iii) a second target-binding domain.

### Claim at position 26

-44. (canceled)

### Claim 45 (depends on 14)

The method of claim 14, wherein the tissue factor-containing protein is a multi-chain chimeric polypeptide.

### Claim 46 (depends on 45)

The method of claim 45, wherein the multi-chain chimeric polypeptide comprises:
(a) a first chimeric polypeptide comprising:
(i) a first target-binding domain;
(ii) a soluble tissue factor domain; and
(iii) a first domain of a pair of affinity domains;
(b) a second chimeric polypeptide comprising:
(i) a second domain of a pair of affinity domains; and
(ii) a second target-binding domain,
wherein the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains.

### Claim at position 29

-68. (canceled)

### Claim 69 (depends on 14)

A tissue factor-containing protein manufactured by the method of claim 14.

### Claim 70 (depends on 69)

A pharmaceutical composition comprising the manufactured tissue factor-containing protein of claim 69.
